Core Viewpoint - Aquestive Therapeutics, Inc. is actively engaging with investors through participation in three upcoming conferences in September 2025, showcasing its commitment to transparency and investor relations [1]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [2]. - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive and inconvenient standard therapies [2]. - Currently, Aquestive has four commercialized products marketed by its licensees globally and is the exclusive manufacturer of these products [2]. - The company collaborates with other pharmaceutical firms to bring new molecules to market using proprietary technologies, such as PharmFilm [2]. - A late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, is under development, along with an early-stage epinephrine prodrug topical gel for dermatological conditions like alopecia areata [2]. Upcoming Events - The company will participate in the Cantor Healthcare Conference with a fireside chat scheduled for 8:00 am ET on September 4, 2025, and will host investor meetings on September 3 and 4 [4]. - At the Wells Fargo Healthcare Conference, the company will be available for investor meetings on September 5 [4]. - The H.C. Wainwright 26th Annual Global Investor Conference will feature a presentation at 10:00 am ET on September 9, 2025, with investor meetings available on September 8 and 9 [4].

Core Viewpoint - Aquestive Therapeutics is advancing its regulatory strategy for Anaphylm™ (epinephrine) Sublingual Film, with meetings scheduled with Health Canada and the European Medicines Agency, aiming to provide a needle-free treatment option for anaphylaxis [1][2][4]. Regulatory Strategy - The company has received a meeting with Health Canada to discuss its New Drug Submission for Anaphylm™ and has submitted an initial briefing book to the EMA [1][8]. - A Marketing Authorization Application (MAA) is planned for submission to the EMA as soon as possible [1][2]. Product Overview - Anaphylm™ is an orally administered epinephrine product that addresses issues related to traditional auto-injectors, such as needle phobia and device malfunctions [3][6]. - The product is designed to be portable, weather-resistant, and easy to use, requiring no water or swallowing for administration [6]. Market Focus - The company's ex-U.S. regulatory strategy targets markets with significant unmet medical needs, with Canada and the EMA being prioritized due to their supportive regulatory environments [4][5]. - The company aims to establish Anaphylm as the new standard of care for severe allergic reactions and anaphylaxis globally [5]. Company Background - Aquestive Therapeutics has a portfolio of six FDA-approved drugs and a global presence across six continents, which enhances its ability to navigate international regulatory processes [2][7]. - The company is also developing other product candidates, including a topical gel for dermatological conditions [7].